[
    [
        {
            "time": "2021-11-28",
            "original_text": "在李佳琦的直播间里，看不到华熙生物的未来",
            "features": {
                "keywords": [
                    "李佳琦",
                    "直播间",
                    "华熙生物",
                    "未来"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "美妆",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "在李佳琦的直播间里，看不到华熙生物的未来",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "最高预售量69万+，双十一国牌美妆大卖，背后受益公司是谁？",
            "features": {
                "keywords": [
                    "预售量",
                    "双十一",
                    "国牌美妆",
                    "受益公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "美妆"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "最高预售量69万+，双十一国牌美妆大卖，背后受益公司是谁？",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "A股资金流向：周期股下挫，新能源板块出现剧烈分歧",
            "features": {
                "keywords": [
                    "A股",
                    "资金流向",
                    "周期股",
                    "新能源板块"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源",
                    "周期股"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股资金流向：周期股下挫，新能源板块出现剧烈分歧",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "受高额营销费拖累，华熙生物三季度净利增速放缓至14％ 盈利能力下降",
            "features": {
                "keywords": [
                    "高额营销费",
                    "华熙生物",
                    "净利增速",
                    "盈利能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "受高额营销费拖累，华熙生物三季度净利增速放缓至14％ 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "信达证券维持华熙生物买入评级：功能性化妆品持续高增，原料业务加速",
            "features": {
                "keywords": [
                    "信达证券",
                    "华熙生物",
                    "功能性化妆品",
                    "原料业务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "化妆品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "信达证券维持华熙生物买入评级：功能性化妆品持续高增，原料业务加速",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "国元证券维持华熙生物买入评级：收入持续高速增长，四大业务板块协同发展",
            "features": {
                "keywords": [
                    "国元证券",
                    "华熙生物",
                    "收入增长",
                    "业务板块"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国元证券维持华熙生物买入评级：收入持续高速增长，四大业务板块协同发展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "东吴证券维持华熙生物买入评级：营收保持高增，功能性护肤主要品牌费用率趋于改善",
            "features": {
                "keywords": [
                    "东吴证券",
                    "华熙生物",
                    "营收",
                    "功能性护肤"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "护肤品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券维持华熙生物买入评级：营收保持高增，功能性护肤主要品牌费用率趋于改善",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "华熙生物前三季度1.92亿元研发费用，传递出什么关键信息？",
            "features": {
                "keywords": [
                    "华熙生物",
                    "研发费用",
                    "关键信息"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华熙生物前三季度1.92亿元研发费用，传递出什么关键信息？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "东方财富证券维持华熙生物增持评级，2021年三季报点评：功能护肤品收入大幅增长",
            "features": {
                "keywords": [
                    "东方财富证券",
                    "华熙生物",
                    "功能护肤品",
                    "收入增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "护肤品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东方财富证券维持华熙生物增持评级，2021年三季报点评：功能护肤品收入大幅增长",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "华熙生物（688363）：前端运营良好，费用侵蚀业绩，长逻辑不变",
            "features": {
                "keywords": [
                    "华熙生物",
                    "前端运营",
                    "费用侵蚀",
                    "业绩"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华熙生物（688363）：前端运营良好，费用侵蚀业绩，长逻辑不变",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]